CGS 15873AAlternative Names: CGS 15873
Latest Information Update: 05 Feb 1997
At a glance
- Originator Novartis
- Class Antipsychotics
- Mechanism of Action Dopamine receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease; Psychotic disorders
Most Recent Events
- 05 Feb 1997 No-Development-Reported for Psychotic disorders in USA (PO)
- 05 Feb 1997 No-Development-Reported for Parkinson's disease in USA (Unknown route)